Telocinobufagin suppresses malignant metastasis of undifferentiated thyroid carcinoma via modulation of the LARP1‐mTOR pathway
Authors:
Open Access
- 9 January 2025
- journal article
- research article
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 41 (3) , e12934
Abstract
Metastasis is the trigger of death in anaplastic thyroid cancer (ATC) patients, yet the specific mechanisms at play are still largely enigmatic. While the involvement of LARP1 in the metastatic process of various cancers has been documented, there is a noticeable gap in the literature regarding its potential influence on ATC metastasis. Molecular studies probed LARP1 expression within ATC cells, with subsequent in vitro experiments examining the effects of LARP1 on ATC cell metastasis and the mTOR signaling cascade. A suite of assays, including colony formation, scratch wound healing, transwell invasion, and cell adhesion, was used to assess cell growth, movement, invasion, and attachment. Western Blot determined the expression levels of epithelial–mesenchymal transition (EMT) markers (E‐cadherin, Vimentin, N‐cadherin) and proteins implicated in metastasis (MMP‐2, MMP‐9), along with mTOR and p‐mTOR. The affinity of Telocinobufagin (TBG) from Yuanhua Toad Essence for LARP1 was investigated through molecular docking, with CETSA assays providing subsequent validation. Further cellular experiments substantiated the influence of TBG on ATC cell metastasis and modulation in the mTOR pathway. LARP1 levels were heightened in ATC cells, and its depletion effectively curbs their proliferative, migratory, invasive, and adhesive activities. With LARP1 knockdown, we also observed that the onset of EMT and metastatic processes was thwarted, as was the mTOR pathway. Subsequent research has uncovered that TBG formed a physical complex with LARP1, allowing it to target and suppress the mTOR pathway, thus preventing the metastasis of ATC. The simultaneous overexpression of LARP1, however, lessened the ability of TBG to inhibit ATC metastasis. This study highlights the importance of TBG binding to LARP1 in the mediation of the mTOR signaling pathway, a key process in the inhibition of ATC cell metastasis. This discovery introduces a new target for the diagnosis of ATC and enlightens the consideration of TBG as a treatment for ATC metastasis.Keywords
This publication has 32 references indexed in Scilit:
- Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cellsPhytomedicine, 2024
- O‐GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/β‐catenin signallingClinical and Translational Medicine, 2023
- Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathwayEuropean Journal of Pharmacology, 2023
- Anaplastic Thyroid CancerEndocrinology and Metabolism Clinics of North America, 2022
- Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 SignalingJournal of Natural Products, 2022
- Global analysis of RNA-binding proteins identifies a positive feedback loop between LARP1 and MYC that promotes tumorigenesisCellular and Molecular Life Sciences, 2022
- Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) processBiochimie, 2019
- The role of LARP1 in translation and beyondWIREs RNA, 2015
- Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infectionInternational Immunopharmacology, 2015
- LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionOncogene, 2014